Acest site necesită browser-ul să fie activat JavaScript.
Vă rugăm să activați JavaScript și să reîncărcați această pagină.
Site-ul necesită browser-ul pentru a activa cookie-urile pentru a se autentifica.
Vă rugăm să activați cookie-urile și reîncărcați această pagină.
Carte romana
Carte rusa
Carte engleza
Vezi toate cartile
Top branduri cosmetica
Cosmetica Coreeana
Machiaj
Ingrijire ten
Ingrijire par
Ingrijire corp
Produse de baie
Igiena orala
Igiena intima
Igiena sexuala
Cosmetice barbati
Seturi cadou
Naturale si organice
Vezi toate cosmeticele
Top branduri dermatocosmetica
Protectie solara
Seturi cadou si pachete promo
Parfumuri pentru femei
Top branduri femei
Premium brands femei
Parfumuri unisex
Vezi toate parfumurile
Parfumuri pentru barbati
Top branduri barbati
Premium brands barbati
Jucarii si jocuri
Hrana si articole copii
Scutece si servetele
Rechizite si papetarie
Vezi toate produsele
Genti & Accesorii
Bijuterii
Ochelari de soare femei
Ochelari de soare barbati
Top Branduri Genti
Top Branduri Bijuterii
Rame ochelari
Vezi toti ochelarii de soare
Imbracaminte
Ceasuri de dama
Top branduri Ceasuri de Dama
Ceasuri barbatesti
Top branduri Ceasuri Barbatesti
Vezi toate ceasurile
Nutritie & Suplimente
Branduri
Curatenie si intretinere
Bucatarie si servirea mesei
Textile camera
Covoare
Decoratiuni
Vinayak K. PrasadMalignant: How Bad Policy and Bad Evidence Harm People with Cancer, Hardcover
în Pickup Point de la 599.99 MDL
în 14 de zile
înainte de plată
Each week, people read about new and exciting cancer drugs. Some of these drugs are truly transformative, offering major improvements in how long patients live or how they feel--but what is often missing from the popular narrative is that, far too often, these new drugs have marginal or minimal benefits. Some are even harmful. In Malignant, hematologist-oncologist Dr. Vinayak K. Prasad writes about the many sobering examples of how patients are too often failed by cancer policy and by how oncology is practiced. Throughout this work, Prasad illuminates deceptive practices which
- promote novel cancer therapies long before credible data are available to support such treatment; and- exaggerate the potential benefits of new therapies, many of which cost thousands and in some cases hundreds of thousands of dollars.
Prasad then critiques the financial conflicts of interest that pervade the oncology field, the pharmaceutical industry, and the US Food and Drug administration.
This is a book about how the actions of human beings--our policies, our standards of evidence, and our drug regulation--incentivize the pursuit of marginal or unproven therapies at lofty and unsustainable prices. Prasad takes us through how cancer trials are conducted, how drugs come to market, and how pricing decisions are made, asking how we can ensure that more cancer drugs deliver both greater benefit and a lower price. Ultimately, Prasad says,
- more cancer clinical trials should measure outcomes that actually matter to people with cancer;- patients on those trials should look more like actual global citizens;- we need drug regulators to raise, not perpetually lower, the bar for approval; and- we need unbiased patient advocates and experts.
This well-written, opinionated, and engaging book explains what we can do differently to make serious and sustained progress against cancer--and how we can avoid repeating the policy and practice mistakes of the past.
Vinayak K. Prasad, MD, MPH is a practicing hematologist-oncologist and internal medicine physician. An associate professor of medicine and public health at Oregon Health & Science University, he is the coauthor of Ending Medical Reversal: Improving Outcomes, Saving Lives.
Am aprecia părerea ta! Evaluați acest produs
Nu există comentarii de la alți utilizatori.